[Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer].

Pancreatic cancer is a highly malignant tumor. About 75% of patients with pancreatic cancer who underwent radical surgical resection will still experience postoperative recurrence. Neoadjuvant therapy could improve outcomes in patients with borderline resectable pancreatic cancer,has become a consensus;however it is still controversial in resectable pancreatic cancer. Limited high-quality randomized controlled trial studies support the routine initiation of neoadjuvant therapy in resectable pancreatic cancer. With the development of new technologies, such as next-generation sequencing, liquid biopsy, imaging omics, and organoids, patients are expected to benefit from the precision screening of potential candidates for neoadjuvant therapy and individualized treatment strategy.胰腺癌的恶性程度高，约75%接受根治性手术的患者会出现术后复发。新辅助治疗可改善交界可切除胰腺癌患者预后，但其在可切除胰腺癌中的应用价值尚存在争议。目前缺乏高质量的随机对照试验研究结果支持对可切除胰腺癌患者常规开展新辅助治疗。随着二代测序、液体活检、影像组学、类器官等新技术的发展，精准筛选新辅助治疗潜在获益人群，个体化选择新辅助治疗方案有望使患者获益。.